Tauklarify is a radioactive imaging agent the FDA approved on August 14, 2026, for brain PET scans in adults being evaluated for Alzheimer's disease, including people with mild cognitive impairment (MCI) the FDA approval notice. A positive scan does not reliably confirm tau pathology on its own, and the approval data show real limits on how confidently any single result should be read.
For someone with MCI, this matters because the diagnostic question at this stage is rarely settled. Tauklarify, known generically as florquinitau F 18 (also called MK-6240), is designed to detect tau neurofibrillary tangles, one of the two hallmark brain changes in Alzheimer's. Understanding what the scan can and cannot tell you is the difference between using it as one piece of evidence and mistaking it for a verdict.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from Lantheus — Use this primary source to verify the official guidance.
- Explore the official data from Psychiatrictimes — Use this primary source to review the underlying data.
Table of Contents
- What Tauklarify Actually Does
- How Accurate Is a Positive Result?
- Why a Positive Scan Isn't a Diagnosis
- Factors That Can Change What the Scan Shows
- What This Means for a Person With MCI Weighing the Scan
- Frequently Asked Questions
What Tauklarify Actually Does
Tauklarify is injected into the bloodstream and binds to tau neurofibrillary tangles in the brain, which then show up on a PET scan. The agent's clinical trials enrolled 617 people across three groups: those with mild cognitive impairment, those with mild Alzheimer's dementia, and cognitively unimpaired volunteers, according to the Society of Nuclear Medicine and Molecular Imaging. That means people with MCI were not an afterthought in the approval data — they were one of the three populations the trials were built around.
The scan itself carries low physical risk. Safety was evaluated in 1,734 subjects, and the most common side effects were headache (0.7%), nausea (0.2%), and injection-site reactions (0.1%), according to the Lantheus prescribing information summarized by Drugs.com. The open question with Tauklarify isn't whether the scan is safe — it's how much weight to put on what the picture shows.
How Accurate Is a Positive Result?
In the two pivotal studies that supported approval, independent blinded readers classified scans as positive or negative for tau pathology and were compared against a reference standard. Positive percent agreement — how often a positive scan correctly matched confirmed tau pathology — ran 80–88% in Study 1 but only 68–82% in Study 2, according to Lantheus's data reported by Psychiatric Times. In practical terms, a positive scan in Study 2 was wrong — compared to the reference standard — as often as roughly one time in three. Negative results performed better.
Negative percent agreement was 93–99% across both studies, according to the FDA approval notice, meaning a negative Tauklarify scan is considerably more reliable at ruling tau pathology out than a positive scan is at ruling it in. For someone with MCI who gets a negative result, that's a stronger piece of evidence against Alzheimer's-type tau pathology than a positive result is evidence for it. Reader-to-reader agreement was high — a statistical measure called Fleiss' kappa came in at 0.92 in Study 1 and 0.86 in Study 2, according to Drugs.com. That means different radiologists tended to agree with each other on what they saw. It does not mean they agreed with the ground truth; consistent readers can consistently misread the same scan.
Why a Positive Scan Isn't a Diagnosis
Independent clinical guidance from the Alzheimer's Association states that a positive tau PET scan does not by itself confirm an Alzheimer's diagnosis, and results must be interpreted together with the full clinical picture, according to its appropriate-use framework. For MCI specifically, that caution carries extra weight because memory and thinking changes at this stage can stem from several different causes, not only Alzheimer's. A 2020 study in the European Journal of Nuclear Medicine and Molecular Imaging found that a substantial share of amyloid-positive patients clinically diagnosed with MCI or Alzheimer's dementia were tau PET-negative, while some cognitively unimpaired people tested tau PET-positive, according to the published findings.
That mismatch between scan result and clinical status is exactly the kind of discordance a person with MCI and their care team need to anticipate before treating any single scan as conclusive. The FDA label reinforces this boundary directly: safety and effectiveness have not been established for using Tauklarify to evaluate non-Alzheimer's tauopathies, such as progressive supranuclear palsy or corticobasal degeneration, according to reporting on the approval. A positive scan in someone with an atypical neurological presentation cannot be read the same way as a positive scan in someone with a more classic Alzheimer's-type picture.
Factors That Can Change What the Scan Shows
Certain everyday factors can interfere with image quality before the scan even happens. Patients are instructed to stop smoking or other tobacco use, along with CYP1A2-inducing medications, at least seven days beforehand, because these can lower the tracer's signal and make the resulting images harder to interpret, according to the prescribing information.
Skipping this step doesn't make a scan unsafe, but it can make an otherwise clear result ambiguous. This is one of the more practical pieces of the puzzle for an MCI patient preparing for the scan: confirming with the ordering clinician which medications and habits need to pause, and for how long, before the appointment. A technically imperfect scan compounds the interpretation uncertainty that's already built into the test's accuracy numbers.
What This Means for a Person With MCI Weighing the Scan
Put together, the numbers suggest a specific way to weigh a result rather than treat it as a yes-or-no answer: The practical takeaway for MCI patients and families is to ask the ordering physician how a given result — positive or negative — will be weighed against other findings, rather than asking only what the scan itself shows.
- A negative scan (93–99% negative percent agreement) is strong evidence against Alzheimer's-type tau pathology.
- A positive scan (68–88% positive percent agreement, varying by study) is suggestive but carries a real chance of not matching the true biological picture.
- Neither result stands alone — it belongs alongside cognitive testing, clinical history, and other biomarker results, per Alzheimer's Association guidance.
- Reader consistency (the high kappa scores) reflects agreement between radiologists, not confirmation that the read is biologically correct.
- Pre-scan instructions around smoking and certain medications affect image quality and should be confirmed with the ordering provider in advance.
Frequently Asked Questions
Does a positive Tauklarify scan confirm Alzheimer's disease in someone with MCI?
No. Alzheimer's Association guidance states a positive tau PET result must be interpreted alongside clinical evaluation, not treated as a standalone diagnosis, per its appropriate-use framework.
Is a negative scan more trustworthy than a positive one?
Yes. Negative percent agreement was 93–99% across the pivotal studies, compared with 68–88% positive percent agreement, according to the FDA approval notice.
Can Tauklarify be used to evaluate conditions other than Alzheimer's-related MCI?
The FDA label states effectiveness has not been established for non-Alzheimer's tauopathies like progressive supranuclear palsy, according to reporting on the approval.
What should someone do before the scan to protect accuracy?
Confirm with the provider about stopping smoking and CYP1A2-inducing medications at least seven days beforehand, per the prescribing information.
You Might Also Like
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Result Interpretation Questions for People With Mild Cognitive Impairment
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Result Interpretation Questions for People With Mild Cognitive Impairment
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Result Interpretation Questions for People With Mild Cognitive Impairment
